NPI: 1760441075 · RANDALLSTOWN, MD 21133 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/23/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/23/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,207 | $10K |
| 2019 | 4,057 | $35K |
| 2020 | 2,172 | $56K |
| 2021 | 2,311 | $52K |
| 2022 | 2,106 | $47K |
| 2023 | 2,459 | $48K |
| 2024 | 2,222 | $82K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 5,922 | 631 | $285K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 103 | 64 | $18K |
| 83970 | 526 | 457 | $15K | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 3,632 | 234 | $9K |
| J1270 | Injection, doxercalciferol, 1 mcg | 3,611 | 315 | $1K |
| A4657 | Syringe, with or without needle, each | 1,411 | 837 | $797.83 |
| 82728 | 291 | 247 | $0.00 | |
| 83550 | 250 | 207 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 155 | 72 | $0.00 |
| 85048 | 666 | 599 | $0.00 | |
| 85041 | 664 | 598 | $0.00 | |
| 83540 | 291 | 247 | $0.00 | |
| 82108 | 12 | 12 | $0.00 |